In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer gets Phase II brain cancer vaccine from Celldex; later returns rights

Executive Summary

Pfizer received exclusive worldwide rights from Avant's wholly owned Celldex Therapeutics division to a Phase II CDX110 vaccine for glioblastoma multiforme (GBM) and other cancer vaccines that target the epidermal growth factor receptor variant vIII (EGFRvIII).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register